GlaxoSmithKline PLC Corporate executive team changes (5835U)

TIDMGSK

RNS Number : 5835U

GlaxoSmithKline PLC

19 January 2017

Issued: Thursday 19 January 2017, London UK - LSE Announcement

Abbas Hussain to leave GSK

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Abbas Hussain, President, Global Pharmaceuticals has decided to leave the company. He has agreed with GSK that he will leave the company later this year.

Abbas joined GSK in 2008 and has held roles of increasing responsibility within the company's pharmaceutical business. He is a member of GSK's executive team and a board member of ViiV Healthcare.

Under his leadership, pharmaceutical and vaccine commercial performance in the US and European businesses has significantly improved, and the company has delivered a series of successful new product launches. At the last reported quarter, new pharmaceutical sales represented 25% of total pharmaceutical sales.

He has also built the world's leading emerging markets pharmaceuticals business by volume, and implemented a flexible approach to pricing across developing countries, helping GSK top the Access to Medicine Index each time since its 2008 launch.

Abbas successfully led the implementation of GSK's new commercial operating model across more than 100 countries, bringing increased transparency to GSK's interactions with healthcare professionals.

Sir Andrew Witty, CEO, GSK commented, "In his time at GSK Abbas has proven himself to be one of the most talented and authentic leaders in the healthcare industry. I am personally grateful for his tremendous energy and support as a member of our executive team. Succession processes are challenging for everyone involved and, unfortunately, it is rare that all of those involved stay with the company. I wish him well in his future and thank him for the significant contribution he has made to GSK and the lives of many patients around the world."

-Ends-

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

 
 GSK enquiries: 
 UK Media enquiries:   David Mawdsley     +44 (0) 20    (London) 
                                           8047 5502 
                       Simon Steel        +44 (0) 20    (London) 
                                           8047 5502 
                       Anna Carruth       +44 (0) 20    (London) 
                                           8047 5502 
 
 US Media enquiries:   Sarah Alspach      +1 202 715    (Washington, 
                                           1048          DC) 
                       Sarah Spencer      +1 215 751    (Philadelphia) 
                                           3335 
 
 Analyst/Investor      Sarah Elton-Farr   +44 (0) 20    (London) 
  enquiries:                               8047 5557 
                       Tom Curry          + 1 215 751   (Philadelphia) 
                                           5419 
                       Gary Davies        +44 (0) 20    (London) 
                                           8047 5503 
                       James Dodwell      +44 (0) 20    (London) 
                                           8047 2406 
                       Jeff McLaughlin    +1 215 751    (Philadelphia) 
                                           7002 
 

Inside information

The information contained in this announcement is inside information. If you have any queries on this, then please contact Victoria Whyte GSK Company Secretary (responsible for arranging the release of this announcement) at GSK House Brentford, Middlesex, TW8 9GS on [phone].

 
 Cautionary statement regarding forward-looking 
  statements 
  GSK cautions investors that any forward-looking 
  statements or projections made by GSK, including 
  those made in this announcement, are subject 
  to risks and uncertainties that may cause actual 
  results to differ materially from those projected. 
  Such factors include, but are not limited to, 
  those described under Item 3.D 'Risk factors' 
  in the company's Annual Report on Form 20-F for 
  2015. 
 
 
 Registered in England & Wales: 
  No. 3888792 
 
 Registered Office: 
  980 Great West Road 
  Brentford, Middlesex 
  TW8 9GS 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUKVNRBBAAARR

(END) Dow Jones Newswires

January 19, 2017 02:00 ET (07:00 GMT)